|
|---|
|
Strother MC,
Kutikov A,
Epstein M,
Bochner E,
Deng M,
Handorf E,
Lewis B,
Ghatalia P,
Greenberg RE,
Chen D,
Viterbo R,
Anari F,
Smaldone MC,
Zibelman MR,
Uzzo RG,
Plimack ER,
Geynisman DM. Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction.
BJU Int. 2021 Mar 29
. |
|
Zibelman M,
Asghar AM,
Parker DC,
O'Neill J,
Wei S,
Greenberg RE,
Smaldone MC,
Chen DYT,
Viterbo R,
Uzzo RG,
Bloom E,
Kokate R,
Geynisman DM,
Ghatalia P,
Deng M,
Ross EA,
Plimack E,
Abbosh PH,
Kutikov A. Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
J Urol. 2021 Feb 4
:101097ju0000000000001602. |
|
Ward WH,
Meeker CR,
Handorf E,
Hill MV,
Einarson M,
Alpaugh RK,
Holden TL,
Astsaturov I,
Denlinger CS,
Hall MJ,
Reddy SS,
Sigurdson ER,
Dotan E,
Zibelman M,
Meyer JE,
Farma JM,
Vijayvergia N. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer.
JCO Clin Cancer Inform. 2021 Jan;5
:125-133. |
|
Miron B,
Xu D,
Zibelman M. Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond.
J Pers Med. 2020 Nov 13;10(4)
. PMC ID:PMC7712808. |
|
Geynisman DM,
Kadow BT,
Shuch BM,
Boorjian SA,
Matin SF,
Rampersaud E,
Milestone BN,
Plimack ER,
Zibelman MR,
Kutikov A,
Smaldone MC,
Chen DY,
Viterbo R,
Joshi S,
Greenberg RE,
Malizzia L,
McGowan T,
Ross EA,
Uzzo RG. Reply by Authors.
J Urol. 2020 Sep;204(3)
:536-537. |
|
Geynisman DM,
Kadow BT,
Shuch BM,
Boorjian SA,
Matin SF,
Rampersaud E,
Milestone BN,
Plimack ER,
Zibelman MR,
Kutikov A,
Smaldone MC,
Chen DY,
Viterbo R,
Joshi S,
Greenberg RE,
Malizzia L,
McGowan T,
Ross EA,
Uzzo RG. Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial.
J Urol. 2020 Sep;204(3)
:531-537. PMC ID:PMC7695484. |
|
Miron B,
Hoffman-Censits JH,
Anari F,
O'Neill J,
Geynisman DM,
Zibelman MR,
Kutikov A,
Viterbo R,
Greenberg RE,
Chen D,
Lallas CD,
Trabulsi EJ,
Alpaugh RK,
Dulaimi E,
Golemis EA,
Uzzo R,
Ross EA,
Plimack ER. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2020 Aug;3(4)
:544-547. PMC ID:PMC7689684. |
|
Zhang T,
Pabla S,
Lenzo FL,
Conroy JM,
Nesline MK,
Glenn ST,
Papanicolau-Sengos A,
Burgher B,
Giamo V,
Andreas J,
Wang Y,
Bshara W,
Madden KG,
Shirai K,
Dragnev K,
Tafe LJ,
Gupta R,
Zhu J,
Labriola M,
McCall S,
George DJ,
Ghatalia P,
Dayyani F,
Edwards R,
Park MS,
Singh R,
Jacob R,
George S,
Xu B,
Zibelman M,
Kurzrock R,
Morrison C. Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
OncoImmunology. 2020 Jun 10;9(1)
:1773200. PMC ID:PMC7458647. |
|
Dawson NA,
Zibelman M,
Lindsay T,
Feldman RA,
Saul M,
Gatalica Z,
Korn WM,
Heath EI. An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer.
Mol Cancer Ther. 2020 Jun;19(6)
:1373-1382. |
|
Zarrabi K,
Masic S,
Schaefer C,
Bartel MJ,
Kutikov A,
Zibelman M. Neoadjuvant checkpoint inhibition in renal cell carcinoma associated Stauffer's syndrome.
Urol Case Rep. 2020 Mar;29
:101077. PMC ID:PMC6911965. |
|
Joshi SS,
Handorf ER,
Sienko D,
Zibelman M,
Uzzo RG,
Kutikov A,
Horwitz EM,
Smaldone MC,
Geynisman DM. Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer.
Eur Urol Oncol. 2020 Feb;3(1)
:104-111. PMC ID:PMC7649050. |
|
Ghatalia P,
Zibelman M,
Geynisman DM,
Plimack ER. First-line Immunotherapy in Metastatic Urothelial Carcinoma.
Eur Urol Focus. 2020 Jan 15;6(1)
:45-47. |
|
Zibelman M,
Plimack ER. Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?.
Ann Transl Med. 2019 Jul;7(Suppl 3)
:S95. PMC ID:PMC6685891. |
|
Osterman CK,
Babu DS,
Geynisman DM,
Lewis B,
Somer RA,
Balar AV,
Zibelman MR,
Guancial EA,
Antinori G,
Yu S,
Narayan V,
Guzzo TJ,
Plimack ER,
Vaughn DJ,
Fung C,
Mamtani R. Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.
Oncologist. 2019 May;24(5)
:688-690. PMC ID:PMC6516116. |
|
Rouvinov K,
Plimack ER,
Zibelman M,
Ghatalia P,
Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma.
Clin Adv Hematol Oncol. 2019 Mar;17(3)
:176-183. |
|
Pabla S,
Conroy JM,
Nesline MK,
Glenn ST,
Papanicolau-Sengos A,
Burgher B,
Hagen J,
Giamo V,
Andreas J,
Lenzo FL,
Yirong W,
Dy GK,
Yau E,
Early A,
Chen H,
Bshara W,
Madden KG,
Shirai K,
Dragnev K,
Tafe LJ,
Marin D,
Zhu J,
Clarke J,
Labriola M,
McCall S,
Zhang T,
Zibelman M,
Ghatalia P,
Araujo-Fernandez I,
Singavi A,
George B,
MacKinnon AC,
Thompson J,
Singh R,
Jacob R,
Dressler L,
Steciuk M,
Binns O,
Kasuganti D,
Shah N,
Ernstoff M,
Odunsi K,
Kurzrock R,
Gardner M,
Galluzzi L,
Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
J Immunother Cancer. 2019 Feb 1;7(1)
:27. PMC ID:PMC6359802. |
|
Conroy JM,
Pabla S,
Nesline MK,
Glenn ST,
Papanicolau-Sengos A,
Burgher B,
Andreas J,
Giamo V,
Wang Y,
Lenzo FL,
Bshara W,
Khalil M,
Dy GK,
Madden KG,
Shirai K,
Dragnev K,
Tafe LJ,
Zhu J,
Labriola M,
Marin D,
McCall SJ,
Clarke J,
George DJ,
Zhang T,
Zibelman M,
Ghatalia P,
Araujo-Fernandez I,
de la Cruz-Merino L,
Singavi A,
George B,
MacKinnon AC,
Thompson J,
Singh R,
Jacob R,
Kasuganti D,
Shah N,
Day R,
Galluzzi L,
Gardner M,
Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
J Immunother Cancer. 2019 Jan 24;7(1)
:18. PMC ID:PMC6346512. |
|
Cole S,
Zibelman M,
Bertino E,
Yucebay F,
Reynolds K. Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions.
Am Soc Clin Oncol Educ Book. 2019 Jan;39
:96-104. |
|
Ghatalia P,
Zibelman MR,
Geynisman DM,
Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.
Clin Adv Hematol Oncol. 2018 Oct;16(10)
:677-686. |
|
Joshi SS,
Handorf EA,
Zibelman M,
Plimack ER,
Uzzo RG,
Kutikov A,
Smaldone MC,
Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Eur Urol. 2018 Sep;74(3)
:387-393. PMC ID:PMC7548437. |
|
Ghatalia P,
Zibelman M,
Geynisman DM,
Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?.
Ther Adv Med Oncol. 2018 Jul;10
:1758835918788310. PMC ID:PMC6066800. |
|
Anari F,
Ramamurthy C,
Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
Future Oncol. 2018 Jun;14(14)
:1409-1421. |
|
Morrison C,
Pabla S,
Conroy JM,
Nesline MK,
Glenn ST,
Dressman D,
Papanicolau-Sengos A,
Burgher B,
Andreas J,
Giamo V,
Qin M,
Wang Y,
Lenzo FL,
Omilian A,
Bshara W,
Zibelman M,
Ghatalia P,
Dragnev K,
Shirai K,
Madden KG,
Tafe LJ,
Shah N,
Kasuganti D,
de la Cruz-Merino L,
Araujo I,
Saenger Y,
Bogardus M,
Villalona-Calero M,
Diaz Z,
Day R,
Eisenberg M,
Anderson SM,
Puzanov I,
Galluzzi L,
Gardner M,
Ernstoff MS. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
J Immunother Cancer. 2018 May 9;6(1)
:32. PMC ID:PMC5944039. |
|
Geynisman DM,
Abbosh PH,
Plimack ER,
Zibelman M. Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
Eur Urol. 2018 May;73(5)
:760-762. |
|
Anari F,
O'Neill J,
Choi W,
Chen DYT,
Haseebuddin M,
Kutikov A,
Dulaimi E,
Alpaugh RK,
Devarajan K,
Greenberg RE,
Bilusic M,
Wong YN,
Viterbo R,
Hoffman-Censits JH,
Lallas CD,
Trabulsi EJ,
Smaldone M,
Geynisman DM,
Zibelman M,
Lin J,
Kelly WK,
Uzzo R,
McConkey D,
Plimack ER. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.
Eur Urol Oncol. 2018 May;1(1)
:54-60. PMC ID:PMC6226048. |
|
Zibelman M,
Plimack ER. Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.
Immunotherapy. 2018 Mar 1;10(6)
:423-425. |
|
Ghatalia P,
Koenigsberg R,
Pisarcik D,
Handorf EA,
Geynisman DM,
Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website.
Kidney Cancer. 2017 Nov 27;1(2)
:151-159. PMC ID:PMC6179107. |
|
Judd J,
Zibelman M,
Handorf E,
O'Neill J,
Ramamurthy C,
Bentota S,
Doyle J,
Uzzo RG,
Bauman J,
Borghaei H,
Plimack ER,
Mehra R,
Geynisman DM. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Oncologist. 2017 Jun 26;22(10)
:1232-1237. PMC ID:PMC5634771. |
|
Zibelman M,
Plimack ER. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
J Natl Compr Canc Netw. 2017 Jun;15(6)
:841-847. |
|
Ghatalia P,
Zibelman M,
Geynisman DM,
Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Curr Treat Options Oncol. 2017 Jan;18(1)
:7. |
|
Zibelman M,
Ramamurthy C,
Plimack ER. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Urol Oncol. 2016 Dec;34(12)
:538-547. |
|
Geynisman DM,
Plimack ER,
Zibelman M. Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?.
Eur Urol. 2016 Dec;70(6)
:971-973. |
|
Zibelman M,
Plimack ER. Systemic therapy for bladder cancer finally comes into a new age.
Future Oncol. 2016 Oct;12(19)
:2227-42. PMC ID:PMC5066115. |
|
Gray PN,
Vuong H,
Tsai P,
Lu HM,
Mu W,
Hsuan V,
Hoo J,
Shah S,
Uyeda L,
Fox S,
Patel H,
Janicek M,
Brown S,
Dobrea L,
Wagman L,
Plimack E,
Mehra R,
Golemis EA,
Bilusic M,
Zibelman M,
Elliott A. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Oncotarget. 2016 Sep 8;7(42)
:68206-68228. PMC ID:PMC5356550. |
|
Zibelman M,
Mehra R. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Am J Clin Oncol. 2016 Aug;39(4)
:396-406. |
|
Zibelman M,
Ghatalia P,
Geynisman DM,
Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.
Immunotherapy. 2016 Jun;8(7)
:785-98. |
|
Zibelman M,
Pollak N,
Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.
J Immunother Cancer. 2016 Feb;4
:8. PMC ID:PMC4754989. |
|
Zibelman M,
Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm.
Oncology (Williston Park). 2016 Feb;30(2)
:160-2, 176. |
|
Zibelman M,
Wong YN,
Devarajan K,
Malizzia L,
Corrigan A,
Olszanski AJ,
Denlinger CS,
Roethke SK,
Tetzlaff CH,
Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Invest New Drugs. 2015 Oct;33(5)
:1040-7. PMC ID:PMC4573837. |
|
Zibelman M,
Barth P,
Handorf E,
Smaldone MC,
Kutikov A,
Uzzo RG,
Bilusic M,
Plimack ER,
Wong YN,
Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite.
Clin Genitourin Cancer. 2015 Apr;13(2)
:142-9. |
|
Godwin JL,
Zibelman M,
Plimack ER,
Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Discov Med. 2014 Dec;18(101)
:341-50. |
|
Zibelman M,
Olszanski AJ. Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma.
J Natl Compr Canc Netw. 2014 Oct 1;12(12 Suppl 2)
:S1-S5. |
|
Zibelman M,
Xiang Q,
Muchka S,
Nickoloff S,
Marks S. Assessing prognostic documentation and accuracy among palliative care clinicians.
J Palliat Med. 2014 May;17(5)
:521-6. |
|
Faculty
Publications
